The earnings call reflected a positive sentiment with notable increases in revenue and strategic collaborations, particularly the landmark deal with BMS. However, the company reported a net loss and anticipated lower COVID-19 vaccination rates, which presented challenges.

Company Guidance

During BioNTech's Second Quarter 2025 Earnings Call, the company provided strategic guidance focused on expanding its oncology portfolio and maintaining its COVID-19 vaccine business. Key metrics included a total revenue of EUR 261 million for the quarter, up from EUR 129 million in the same period last year, driven primarily by COVID-19 vaccine collaboration revenues. Research and development expenses were EUR 509 million, down from EUR 585 million in the previous year due to clinical trial reprioritization. The company reported a net loss of EUR 387 million, significantly reduced from the EUR 808 million loss in the prior year. BioNTech emphasized its collaboration with Bristol-Myers Squibb, expecting a USD 1.5 billion upfront cash payment, and detailed plans for BNT327 and mRNA cancer immunotherapies in ongoing and upcoming clinical trials. The company reaffirmed its 2025 financial guidance, projecting revenues between EUR 1.7 billion and EUR 2.2 billion, and highlighted its strong cash position of EUR 16 billion to support future investments.

Strong Financial Position

BioNTech reported a strong financial position with EUR 16 billion in cash plus security investments, providing flexibility to pursue long-term strategy.

Revenue Increase

Total revenues for Q2 2025 were approximately EUR 261 million, up from EUR 129 million in Q2 2024, driven by COVID-19 vaccine collaboration.

New Strategic Collaborations

BioNTech entered a significant co-development and co-commercialization collaboration with BMS for BNT327, with an upfront payment of USD 1.5 billion.

Advancements in Oncology Pipeline

Initiated two global pivotal clinical trials for BNT327 in first-line small cell and non-small cell lung cancer and planning a third in triple-negative breast cancer.

COVID-19 Vaccine Developments

Preparation for the global rollout of a new variant adapted COVID-19 vaccine for the upcoming season, pending regulatory approvals.

Expansion in the UK

Expanded partnership with the U.K. government to invest up to GBP 1 billion over the coming decade, establishing new R&D centers.

BioNTech SE (DE:22UA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:22UA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 03, 2025	2025 (Q3)	-1.03 / -	0.81	―	―	―
Aug 04, 2025	2025 (Q2)	-2.28 / -1.60	-3.36	52.38% (+1.76)
May 05, 2025	2025 (Q1)	-2.29 / -1.73	-1.31	-32.06% (-0.42)
Mar 10, 2025	2024 (Q4)	0.45 / 1.08	1.9	-43.16% (-0.82)
Nov 04, 2024	2024 (Q3)	-1.56 / 0.81	0.67	20.90% (+0.14)
Aug 05, 2024	2024 (Q2)	-2.05 / -3.36	-0.79	-325.32% (-2.57)
May 06, 2024	2024 (Q1)	-1.24 / -1.31	2.05	-163.90% (-3.36)
Mar 20, 2024	2023 (Q4)	2.38 / 1.90	9.26	-79.48% (-7.36)
Nov 06, 2023	2023 (Q3)	-0.59 / 0.67	6.98	-90.40% (-6.31)
Aug 07, 2023	2023 (Q2)	-0.83 / -0.79	6.45	-112.25% (-7.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:22UA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	€92.05	€97.05	+5.43%
May 05, 2025	€92.60	€89.70	-3.13%
Mar 10, 2025	€101.60	€98.05	-3.49%
Nov 04, 2024	€102.40	€102.20	-0.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.